N

Natera
D

NTRA

167.300
USD
-2.05
(-1.21%)
Market Closed
Volume
60,629
EPS
-2
Div Yield
-
P/E
-95
Market Cap
22,087,082,517
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    D
    DGX
    3.615
    (2.30%)
    160.455 USD
    E
    EXAS
    -1.680
    (-3.29%)
    49.330 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    H
    HZNP
    0
    (0%)
    0.000000 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    513.04 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Natera

Sector: Healthcare
Industry: Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.